Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
ConclusionsIn this post hoc analysis, tirzepatide was associated with reduced blood glucose and body weight in a predominantly Chinese population with T2D across different subgroups, consistent with previous reports for tirzepatide.Clinical Trial RegistrationNCT04093752.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: China Health | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Gastroenterology | Insulin | Lantus | Metformin | Weight Loss